188 related articles for article (PubMed ID: 9834336)
21. Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy.
Micke O; Bruns F; Kurowski R; Horst E; deVries AF; Hausler JW; Willich N; Schäfer U
Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):90-7. PubMed ID: 12909220
[TBL] [Abstract][Full Text] [Related]
22. Preoperative CA 19-9 kinetics as a prognostic variable in radiographically resectable pancreatic adenocarcinoma.
Brown EG; Canter RJ; Bold RJ
J Surg Oncol; 2015 Mar; 111(3):293-8. PubMed ID: 25330934
[TBL] [Abstract][Full Text] [Related]
23. [Tumor markers in the diagnosis of pancreatic cancer].
Cappelli G; Paladini S; D'Agata A
Tumori; 1999; 85(1 Suppl 1):S19-21. PubMed ID: 10235075
[TBL] [Abstract][Full Text] [Related]
24. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy.
Hartwig W; Strobel O; Hinz U; Fritz S; Hackert T; Roth C; Büchler MW; Werner J
Ann Surg Oncol; 2013 Jul; 20(7):2188-96. PubMed ID: 23247983
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours.
Sefrioui D; Blanchard F; Toure E; Basile P; Beaussire L; Dolfus C; Perdrix A; Paresy M; Antonietti M; Iwanicki-Caron I; Alhameedi R; Lecleire S; Gangloff A; Schwarz L; Clatot F; Tuech JJ; Frébourg T; Jardin F; Sabourin JC; Sarafan-Vasseur N; Michel P; Di Fiore F
Br J Cancer; 2017 Sep; 117(7):1017-1025. PubMed ID: 28772284
[TBL] [Abstract][Full Text] [Related]
26. Are elevated levels of the tumour marker CA19-9 of any clinical significance?--an evaluation.
McLaughlin R; O'Hanlon D; Kerin M; Kenny P; Grimes H; Given HF
Ir J Med Sci; 1999; 168(2):124-6. PubMed ID: 10422394
[TBL] [Abstract][Full Text] [Related]
27. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates.
Poruk KE; Gay DZ; Brown K; Mulvihill JD; Boucher KM; Scaife CL; Firpo MA; Mulvihill SJ
Curr Mol Med; 2013 Mar; 13(3):340-51. PubMed ID: 23331006
[TBL] [Abstract][Full Text] [Related]
28. CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer.
Molina V; Visa L; Conill C; Navarro S; Escudero JM; Auge JM; Filella X; Lopez-Boado MA; Ferrer J; Fernandez-Cruz L; Molina R
Tumour Biol; 2012 Jun; 33(3):799-807. PubMed ID: 22203495
[TBL] [Abstract][Full Text] [Related]
29. Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen.
Firpo MA; Gay DZ; Granger SR; Scaife CL; DiSario JA; Boucher KM; Mulvihill SJ
World J Surg; 2009 Apr; 33(4):716-22. PubMed ID: 19082654
[TBL] [Abstract][Full Text] [Related]
30. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer.
Goonetilleke KS; Siriwardena AK
Eur J Surg Oncol; 2007 Apr; 33(3):266-70. PubMed ID: 17097848
[TBL] [Abstract][Full Text] [Related]
31. Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma.
Okada K; Kawai M; Tani M; Hirono S; Miyazawa M; Shimizu A; Kitahata Y; Yamaue H
J Hepatobiliary Pancreat Sci; 2014 Sep; 21(9):648-53. PubMed ID: 24764208
[TBL] [Abstract][Full Text] [Related]
32. Neopterin serum levels in pancreatic adenocarcinoma.
Manes G; Spada OA; Rabitti PG; Feola B; Misso S; Minerva A; Uomo G
Int J Pancreatol; 1999 Feb; 25(1):31-7. PubMed ID: 10211419
[TBL] [Abstract][Full Text] [Related]
33. Re: CA 19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and preoperative therapy.
Bold RJ
Ann Surg Oncol; 2013 Jul; 20(7):2108-10. PubMed ID: 23563959
[No Abstract] [Full Text] [Related]
34. CA 19-9: not a magic marker for pancreatic cancer.
Daram SR
South Med J; 2006 Mar; 99(3):205. PubMed ID: 16553091
[No Abstract] [Full Text] [Related]
35. Clinical value and impact on prognosis of peri-operative CA 19-9 serum levels in stage I and II adenocarcinoma of the pancreas.
Piagnerelli R; Marrelli D; Roviello G; Ferrara F; Di Mare G; Voglino C; Petrioli R; Marini M; Macchiarelli R; Roviello F
Tumour Biol; 2016 Feb; 37(2):1959-66. PubMed ID: 26334620
[TBL] [Abstract][Full Text] [Related]
36. CA 19-9 concentration in peripheral and portal blood of patients operated on for pancreatic tumor.
Szwedziak K; Strzelczyk J
Pol Przegl Chir; 2013 Jan; 85(1):20-8. PubMed ID: 23509198
[TBL] [Abstract][Full Text] [Related]
37. [Differential diagnosis of pancreatic head cancer].
Kubyshkin VA; Vishnevskiĭ VA; Aĭrapetian AT; Karmazanovskiĭ GG; Kuntsevich GI; Starkov IuG
Khirurgiia (Mosk); 2000; (11):19-23. PubMed ID: 11220911
[TBL] [Abstract][Full Text] [Related]
38. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K
J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617
[TBL] [Abstract][Full Text] [Related]
39. Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer.
Ventrucci M; Cipolla A; Racchini C; Casadei R; Simoni P; Gullo L
Dig Dis Sci; 2004 Aug; 49(7-8):1149-55. PubMed ID: 15387337
[TBL] [Abstract][Full Text] [Related]
40. Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma.
Rayamajhi S; Balachandran A; Katz M; Reddy A; Rohren E; Bhosale P
Abdom Radiol (NY); 2018 Feb; 43(2):505-513. PubMed ID: 28900703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
